GlassScriptPhysician profile
Kimberly N Clovis
NPI 1144931536
$13,995.00
in general payments reported to CMS, 2019-2025
37 companies · $3,034 in 2025
The $3,034 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,434 · 2024: $8,526 · 2025: $3,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,256 · Consulting Fee: $5,100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $450 · Long Term Medical Supply Or Device Loan: $110 · Gift: $59.40 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,255.62 |
| Consulting Fee | $5,100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $450.00 |
| Long Term Medical Supply Or Device Loan | $109.98 |
| Gift | $59.40 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $6,533.50 | 2023-2025 | Afrezza, V-Go |
| Lilly USA, LLC | $946.19 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $684.84 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $585.03 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $558.65 | 2023-2025 | |
| Corcept Therapeutics | $535.76 | 2023-2025 | Korlym |
| Beta Bionics, INC. | $384.73 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $379.99 | 2023-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $371.39 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $312.08 | 2023-2025 | Freestyle Copilot, Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $265.33 | 2023-2025 | |
| Medtronic, INC. | $264.96 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $258.26 | 2023-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.67 | 2023-2025 | Jardiance |
| Amgen INC. | $210.23 | 2023-2025 | Tepezza, Evenity, Prolia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $183.30 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $159.62 | 2025 | Twiist |
| Kyowa Kirin, INC. | $147.02 | 2023-2025 | Crysvita |
| Cequr Corporation | $130.18 | 2023-2025 | Cequr Simplicity |
| Endo USA, INC. | $122.21 | 2025 | Aveed |
| Novartis Pharmaceuticals Corporation | $102.78 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $81.75 | 2024-2025 | Isturisa, Signifor Lar |
| Neurocrine Biosciences, INC. | $73.93 | 2024-2025 | |
| Antares Pharma, INC. | $59.28 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Ascendis Pharma Endocrinology INC | $57.08 | 2023-2025 | Yorvipath |
| Pfizer INC. | $46.69 | 2023 | |
| Alexion Pharmaceuticals, INC. | $41.90 | 2023-2025 | Strensiq |
| Abbvie INC. | $40.44 | 2023-2024 | |
| Rhythm Pharmaceuticals, INC. | $40.28 | 2025 | Imcivree |
| Nevro Corp. | $35.29 | 2023 | Senza |
| Tolmar, INC. | $28.11 | 2024-2025 | Jatenzo |
| Amneal Pharmaceuticals LLC | $27.18 | 2023-2024 | Unithroid |
| Lifescan, INC. | $22.60 | 2023 | |
| Ascensia Diabetes Care US INC. | $21.27 | 2025 | |
| Merck Sharp & Dohme LLC | $17.82 | 2023 | Steglujan, Steglatro |
| Esperion Therapeutics, INC. | $17.42 | 2024 | Nexletol |
| Almatica Pharma LLC | $16.24 | 2025 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Clovis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.